Could more complex molecular analysis aid biomarker-driven clinical management of poor-prognosis colorectal cancer?
New study findings provide support for the use of ctDNA to predict survival benefits and personalise treatments
Reshaping the treatment landscape for GI cancers
ADCs are transforming the management of patients with GI cancers, but novel targets and combination strategies will be required to address resistance development and optimise patient outcomes
Adagrasib plus cetuximab fails to outperform chemotherapy in KRAS G12C-mutated metastatic colorectal cancer
The phase III KRYSTAL-10 trial did not meet its co-primary survival endpoints
Targeting the CD47-SIRPα axis continues to show promise in solid tumours
In early-phase studies, two novel agents showed low propensity to induce heamatological toxicities in heavily pre-treated solid tumours
Exploiting HER2 tumour heterogeneity with digital oncology
Multi-regional modelling reveals new ways to personalise treatments in gastric and breast cancers
How to sequence antibody–drug conjugates in metastatic breast cancer? Target switching alone may not be the answer
The first prospective phase II trials evaluating TOPO1 ADC after prior TOPO1 ADC therapy confirm the emergence of cross-resistance
Novel emerging targets, new treatment opportunities
Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context
From bispecific to multispecific antibodies: a highly promising field
Development of therapies modulating two or more targets is increasing rapidly despite facing a number of hurdles
Data show how ESMO’s scales and recommendations can guide the optimisation of outcomes in patients with targetable mutations
In two studies, the use of ESCAT matching and ESMO recommendations for germline assessment lead to effective targeted treatment
Data highlight the clinical feasibility of targeting the CD47-SIRPα axis mediating immunotherapy resistance
Early activity and manageable safety were demonstrated in two phase I trials with innovative agents